Inluriyo
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Inluriyo
- Generic name
- IMLUNESTRANT
- Manufacturer
- Eli Lilly and Company
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 5bc172e4-e8a2-441a-be52-279a7f890196
- SPL ID
- 0f64afa6-a367-4dfe-a0ca-8631aa894f61
- Version
- 8
- Effective date
- 2026-09-18
- Source export date
- 2026-11-13
- Source partition
- 3
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2df682709a18af7b632162dce4573ac151d74d432118e70b8675083d83b89813/drug-label-0003-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:47:23
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 218881 | derived:openfda.application_number |
| application number | NDA218881 | openfda.application_number | |
| brand name | Inluriyo | openfda.brand_name | |
| generic name | IMLUNESTRANT | openfda.generic_name | |
| manufacturer name | Eli Lilly and Company | openfda.manufacturer_name | |
| ndc | package | 0002-1717-56 | openfda.package_ndc |
| ndc | package | 0002-1717-28 | openfda.package_ndc |
| ndc | package | 0002-1717-61 | openfda.package_ndc |
| ndc | product | 0002-1717 | openfda.product_ndc |
| ndc11 | package | 00002171728 | derived:openfda.package_ndc |
| ndc11 | package | 00002171761 | derived:openfda.package_ndc |
| ndc11 | package | 00002171756 | derived:openfda.package_ndc |
| rxcui | 2725923 | openfda.rxcui | |
| rxcui | 2725917 | openfda.rxcui | |
| spl id | 0f64afa6-a367-4dfe-a0ca-8631aa894f61 | id | |
| spl set id | 5bc172e4-e8a2-441a-be52-279a7f890196 | set_id | |
| unii | 9CXQ3PF69U | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Embryo-Fetal Toxicity: INLURIYO can cause fetal harm. Advise of the potential risk to a fetus and to use effective contraception. ( 5.1 , 8.1 , 8.3 ) 5.1 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, INLURIYO can cause fetal harm when administered to a pregnant woman. In an animal reproduction study, oral administration of imlunestrant to pregnant rats during the period of organogenesis led to embryo-fetal mortality and structural abnormalities at maternal exposures that were below the human exposure at the recommended dose based on AUC. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with INLURIYO and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with INLURIYO and for 1 week after the last dose [see Use in Specific Populations ( 8.1 , 8.3 ) and Clinical Pharmacology ( 12.1 )] .
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common (incidence ≥10%) adverse reactions, including laboratory abnormalities, for INLURIYO monotherapy were: decreased hemoglobin, musculoskeletal pain, decreased calcium, decreased neutrophils, increased AST, fatigue, diarrhea, increased ALT, increased triglycerides, nausea, decreased platelets, constipation, increased cholesterol, and abdominal pain. ( 6.1 ) The most common (incidence ≥ 10%) adverse reactions, including laboratory abnormalities, for INLURIYO in combination with abemaciclib were decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, nausea, decreased platelets, fatigue, increased triglycerides, infections, increased AST, increased creatinine, increased ALT, vomiting, musculoskeletal pain, abdominal pain, decreased appetite, increased cholesterol, rash, cough, headache, and decreased weight. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. ER+, HER2-, ESR1 -mutated Advanced or Metastatic Breast Cancer INLURIYO as Monotherapy The safety of INLURIYO was evaluated in 651 patients with ER+, HER2- locally advanced or metastatic breast cancer previously treated with endocrine therapy with or without a prior CDK4/6 inhibitor in EMBER-3 [see Clinical Studies ( 14 )] . Patients received INLURIYO 400 mg orally, once daily (n=327), or standard of care (n=324) consisting of either fulvestrant (n=292) or exemestane (n=32). Among patients who were treated with INLURIYO, the median duration of exposure was 5.6 months (range: 0.2 to 28.6 months) in EMBER-3. Serious adverse reactions occurred in 10% of patients who received INLURIYO. Serious adverse reactions in > 1% of patients included pleural effusion (1.2%). Fatal adverse reactions occurred in 1.8% of patients who received INLURIYO, including cardiac arrest, acute myocardial infarction, right ventricular failure, hypovolemic shock, and upper gastrointestinal hemorrhage (each 0.3%). Permanent treatment discontinuation of INLURIYO due to an adverse reaction occurred in 4.6% of patients. Adverse reactions which resulted in permanent discontinuation of INLURIYO included increased alanine aminotransferase (ALT) (0.9%), abdominal pain, fatigue, fractured sacrum, hepatotoxicity, neuropathy peripheral, and pyrexia (each 0.3%). Dosage interruption of INLURIYO due to an adverse reaction occurred in 10% of patients. Adverse reactions which required dosage interruption in >0.5% were vomiting (1.5%); increased aspartate aminotransferase (AST), and COVID-19 (each 0.9%); and increased ALT, anemia, diarrhea, decreased neutrophil count, and pyrexia (each 0.6%). Dose reductions of INLURIYO due to an adverse reaction occurred in 2.4% of patients. Adverse reactions which required dose reductions were increased AST (0.6%); and increased ALT, anemia, fatigue, interstitial lung disease, nausea, neutropenia, and vomiting (each 0.3%). The most common (≥10%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin, musculoskeletal pain, decreased calcium, decreased neutrophils, increased AST, fatigue, diarrhea, increased ALT, increased triglycerides, nausea, decreased platelets, constipation, increased cholesterol, and abdominal pain. Table 3 summarizes the adverse reactions in EMBER-3. Table 3: Adverse Reactions (≥10%) in Patients Who Received INLURIYO in EMBER-3 a Adverse reactions were graded using NCI CTCAE version 5.0. b Includes other related terms Adverse Reaction a INLURIYO N=327 Fulvestrant or Exemestane N=324 All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Musculoskeletal Disorders Musculoskeletal Pain 30 3.7 29 1.9 General Disorders and Administration Site Conditions Fatigue b 23 0.3 14 0.6 Gastrointestinal Disorders Diarrhea 22 0.6 12 0.0 Nausea 17 0.3 13 0.0 Constipation 10 0 6 0.3 Abdominal pain b 10 0.3 6 0.6 Clinically relevant adverse reactions (<10%) in patients who received INLURIYO included: vomiting (9%), headache (9%), cough (9%), decreased appetite (8%), hot flush (7%), pruritus (3.7%), dyspepsia (2.8%), and stomatitis (2.4%). Table 4 summarizes the laboratory abnormalities in EMBER-3. Table 4: Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received INLURIYO in EMBER-3 a Graded according to NCI CTCAE version 5.0 b The denominator used to calculate the rate varied from 252 to 325 based on the number of patients with a baseline value and at least one post-treatment value. Lab Abnormality a INLURIYO b Fulvestrant or Exemestane b All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Hematology Hemoglobin decreased 30 1.2 35 3.4 Neutrophils decreased 26 4 29 4.7 Platelets decreased 16 1.8 14 1.3 Chemistry Calcium decreased 26 0 19 0.6 AST increased 25 1.9 27 2.3 ALT increased 21 1.3 23 1.0 Triglycerides increased 21 0 22 1.2 Cholesterol increased 10 0 12 0 INLURIYO in Combination with Abemaciclib The safety of INLURIYO in combination with abemaciclib was evaluated in 535 patients with ER+, HER2- locally advanced or metastatic breast cancer previously treated with endocrine therapy with or without a prior CDK4/6 inhibitor in EMBER-3 [see Clinical Studies ( 14 )] . Patients received INLURIYO 400 mg orally once daily in combination with abemaciclib 150 mg twice daily (N=208), or INLURIYO monotherapy 400 mg, once daily (n=327). Among patients who were treated with INLURIYO in combination with abemaciclib, the median duration of exposure was 7.7 months (range 1 day to 25.3 months). Serious adverse reactions occurred in 21% of patients who received INLURIYO in combination with abemaciclib. Serious adverse reactions in >1% of patients included pneumonia (2.4%), abdominal pain, and renal failure (each 1.4%). Fatal adverse reactions occurred in 3.8% of patients who received INLURIYO in combination with abemaciclib, including pneumonia (1.4%), myocardial infarction, interstitial lung disease, and sepsis (0.5% each). Permanent treatment discontinuation of INLURIYO due to an adverse reaction occurred in two patients (1%). The adverse reactions which required permanent discontinuation were increased ALT and anemia (0.5% each). Dosage interruptions of INLURIYO due to an adverse reaction occurred in 50% of patients. Adverse reactions which required dosage interruptions of INLURIYO in ≥2% of patients included diarrhea (14%), neutropenia (9%), decreased neutrophil count (6%), nausea (6%), anemia (6%), increased ALT (2.4%), and vomiting (2.4%). Dose reductions of INLURIYO due to an adverse reaction occurred in 18% of patients. Adverse reactions which required dose reductions of INLURIYO in ≥ 1% of patients included diarrhea (6%), neutropenia (1.9%), nausea (1.9%), increased ALT (1.9%), and decreased neutrophil count (1.4%). The most common (≥10%) adverse reactions, including laboratory abnormalities, were decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, nausea, decreased platelets, fatigue, increased triglycerides, infections, increased AST, increased creatinine, increased ALT, vomiting, musculoskeletal pain, abdominal pain, decreased appetite, increased cholesterol, rash, cough, headache, and decreased weight. Table 5 summarizes the adverse reactions in EMBER-3. Table 5: Adverse Reactions (≥10%) in Patients Who Received INLURIYO in Combination with Abemaciclib in EMBER-3 a Adverse reactions were graded using NCI CTCAE version 5.0. b Includes other related terms Adverse Reaction a INLURIYO plus Abemaciclib N=208 INLURIYO N=327 All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Gastrointestinal Disorders Diarrhea 86 9 23 0.3 Nausea 51 1.9 18 0.3 Vomiting 32 0.5 10 0.6 Abdominal pain b 24 1.9 11 0.3 General Disorders and Administration Site Conditions Fatigue b 41 5 24 0.3 Infections and Infestations Infections b 36 7 25 3.4 Musculoskeletal Disorders Musculoskeletal pain b 25 1.4 31 2.8 Metabolism and Nutrition Disorders Decreased appetite b 22 1 9 0.3 Skin and Subcutaneous Tissue Disorders Rash b 14 1.4 4.9 0 Respiratory, Thoracic and Mediastinal Disorders Cough b 13 0 9 0 Nervous System Disorders Headache b 10 0.5 9 0 Investigations Weight decreased 10 0 4.6 0 Clinically relevant adverse reactions (<10%) in patients who received INLURIYO in combination with abemaciclib included: constipation (9%), stomatitis (9%), fever (9%), urinary tract infection (8%), dizziness (8%), hot flush (6%), insomnia (6%), arrhythmia (6%), alopecia (5%), back pain (4.8%), venous thromboembolic event (4.8%) and interstitial lung disease or pneumonitis (2.9%). Table 6 summarizes the laboratory abnormalities in EMBER-3. Table 6: Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received INLURIYO in Combination with Abemaciclib in EMBER-3 a Graded according to NCI CTCAE version 5. b The denominator used to calculate the frequency varied from 178 to 205 based on the number of patients with a baseline value and at least one post-treatment value. Lab Abnormality a INLURIYO plus Abemaciclib b INLURIYO b All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Hematology Neutrophils decreased 86 21 28 4.3 Hemoglobin decreased 81 9 34 2.2 Lymphocytes decreased 58 9 29 2.2 Platelets decreased 48 2.4 18 2.8 Chemistry Triglycerides increased 40 2.3 22 0 AST increased 36 2.5 27 1.9 Creatinine increased 36 1.1 6 0.3 ALT increased 33 5 22 1.3 Cholesterol increased 18 0 12 0.4
adverse reactions table
<table ID="t3" width="100%"> <caption>Table 3: Adverse Reactions (≥10%) in Patients Who Received INLURIYO in EMBER-3 </caption> <col width="29.186%" align="left"/> <col width="18.344%" align="left"/> <col width="17.504%" align="left"/> <col width="17.363%" align="left"/> <col width="17.604%" align="left"/> <tfoot> <tr> <td colspan="5" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>a</sup> Adverse reactions were graded using NCI CTCAE version 5.0. </paragraph> </td> </tr> <tr> <td colspan="5" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>b</sup> Includes other related terms </paragraph> </td> </tr> </tfoot> <tbody> <tr> <td rowspan="2" align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> <content styleCode="bold">Adverse Reaction</content> <content styleCode="bold"> <sup>a</sup> </content> </td> <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">INLURIYO</content> <content styleCode="bold">N=327</content> </td> <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Fulvestrant or Exemestane</content> <content styleCode="bold">N=324</content> </td> </tr> <tr> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades %</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grades 3 or 4 %</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades %</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grades 3 or 4 %</content> </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Musculoskeletal Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Musculoskeletal Pain </td> <td align="center" valign="top" styleCode="Botrule Rrule">30 </td> <td align="center" valign="top" styleCode="Botrule Rrule">3.7 </td> <td align="center" valign="top" styleCode="Botrule Rrule">29 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.9 </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">General Disorders and Administration Site Conditions</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Fatigue<sup>b</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">23 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3 </td> <td align="center" valign="top" styleCode="Botrule Rrule">14 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Gastrointestinal Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Diarrhea </td> <td align="center" valign="top" styleCode="Botrule Rrule">22 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">12 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Nausea </td> <td align="center" valign="top" styleCode="Botrule Rrule">17 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3 </td> <td align="center" valign="top" styleCode="Botrule Rrule">13 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Constipation </td> <td align="center" valign="top" styleCode="Botrule Rrule">10 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Abdominal pain<sup>b</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">10 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3 </td> <td align="center" valign="top" styleCode="Botrule Rrule">6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> </tr> </tbody> </table>
adverse reactions table
<table ID="t4" width="100%"> <caption>Table 4: Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received INLURIYO in EMBER-3 </caption> <col width="25.265%" align="left"/> <col width="19.344%" align="left"/> <col width="19.324%" align="left"/> <col width="18.484%" align="left"/> <col width="17.584%" align="left"/> <tfoot> <tr> <td colspan="5" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>a</sup> Graded according to NCI CTCAE version 5.0 </paragraph> </td> </tr> <tr> <td colspan="5" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>b</sup> The denominator used to calculate the rate varied from 252 to 325 based on the number of patients with a baseline value and at least one post-treatment value. </paragraph> </td> </tr> </tfoot> <tbody> <tr> <td rowspan="2" align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> <content styleCode="bold">Lab Abnormality</content> <content styleCode="bold"> <sup>a</sup> </content> </td> <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">INLURIYO</content> <content styleCode="bold"> <sup>b</sup> </content> </td> <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Fulvestrant or Exemestane</content> <content styleCode="bold"> <sup>b</sup> </content> </td> </tr> <tr> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades %</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grades 3 or 4 %</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades %</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grades 3 or 4 %</content> </td> </tr> <tr> <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Hematology</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Hemoglobin decreased </td> <td align="center" valign="top" styleCode="Botrule Rrule">30 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">35 </td> <td align="center" valign="top" styleCode="Botrule Rrule">3.4 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Neutrophils decreased </td> <td align="center" valign="top" styleCode="Botrule Rrule">26 </td> <td align="center" valign="top" styleCode="Botrule Rrule">4 </td> <td align="center" valign="top" styleCode="Botrule Rrule">29 </td> <td align="center" valign="top" styleCode="Botrule Rrule">4.7 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Platelets decreased </td> <td align="center" valign="top" styleCode="Botrule Rrule">16 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.8 </td> <td align="center" valign="top" styleCode="Botrule Rrule">14 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.3 </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Chemistry</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Calcium decreased </td> <td align="center" valign="top" styleCode="Botrule Rrule">26 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">19 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> AST increased </td> <td align="center" valign="top" styleCode="Botrule Rrule">25 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">27 </td> <td align="center" valign="top" styleCode="Botrule Rrule">2.3 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> ALT increased </td> <td align="center" valign="top" styleCode="Botrule Rrule">21 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.3 </td> <td align="center" valign="top" styleCode="Botrule Rrule">23 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Triglycerides increased </td> <td align="center" valign="top" styleCode="Botrule Rrule">21 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">22 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.2 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Cholesterol increased </td> <td align="center" valign="top" styleCode="Botrule Rrule">10 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">12 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> </tbody> </table>
adverse reactions table
<table ID="t5" width="100%"> <caption> Table 5: Adverse Reactions (≥10%) in Patients Who Received INLURIYO in Combination with Abemaciclib in EMBER-3 </caption> <col width="32.014%" align="left"/> <col width="16.997%" align="left"/> <col width="16.997%" align="left"/> <col width="16.997%" align="left"/> <col width="16.997%" align="left"/> <tfoot> <tr> <td colspan="5" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>a</sup> Adverse reactions were graded using NCI CTCAE version 5.0.</paragraph> </td> </tr> <tr> <td colspan="5" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>b</sup> Includes other related terms</paragraph> </td> </tr> </tfoot> <tbody> <tr> <td rowspan="2" align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> <content styleCode="bold">Adverse Reaction<sup>a</sup> </content> </td> <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">INLURIYO plus Abemaciclib</content> <content styleCode="bold">N=208</content> </td> <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">INLURIYO</content> <content styleCode="bold">N=327</content> </td> </tr> <tr> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades %</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grades 3 or 4 %</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades %</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grades 3 or 4 %</content> </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Gastrointestinal Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Diarrhea</td> <td align="center" valign="top" styleCode="Botrule Rrule">86</td> <td align="center" valign="top" styleCode="Botrule Rrule">9</td> <td align="center" valign="top" styleCode="Botrule Rrule">23</td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3</td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Nausea</td> <td align="center" valign="top" styleCode="Botrule Rrule">51</td> <td align="center" valign="top" styleCode="Botrule Rrule">1.9</td> <td align="center" valign="top" styleCode="Botrule Rrule">18</td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3</td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Vomiting</td> <td align="center" valign="top" styleCode="Botrule Rrule">32</td> <td align="center" valign="top" styleCode="Botrule Rrule">0.5</td> <td align="center" valign="top" styleCode="Botrule Rrule">10</td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6</td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Abdominal pain<sup>b</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">24</td> <td align="center" valign="top" styleCode="Botrule Rrule">1.9</td> <td align="center" valign="top" styleCode="Botrule Rrule">11</td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3</td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">General Disorders and Administration Site Conditions</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Fatigue<sup>b</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">41</td> <td align="center" valign="top" styleCode="Botrule Rrule">5</td> <td align="center" valign="top" styleCode="Botrule Rrule">24</td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3</td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Infections and Infestations</content> </td> </tr> <tr> <td align="left" valign="middle" styleCode="Botrule Lrule Rrule"> Infections<sup>b</sup> </td> <td align="center" valign="middle" styleCode="Botrule Rrule">36 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">7 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">25 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">3.4 </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Musculoskeletal Disorders</content> </td> </tr> <tr> <td align="left" valign="middle" styleCode="Botrule Lrule Rrule"> Musculoskeletal pain<sup>b</sup> </td> <td align="center" valign="middle" styleCode="Botrule Rrule">25 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">1.4 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">31 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">2.8 </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Metabolism and Nutrition Disorders</content> </td> </tr> <tr> <td align="left" valign="middle" styleCode="Botrule Lrule Rrule"> Decreased appetite<sup>b</sup> </td> <td align="center" valign="middle" styleCode="Botrule Rrule">22 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">1 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">9 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">0.3 </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Skin and Subcutaneous Tissue Disorders </content> </td> </tr> <tr> <td align="left" valign="middle" styleCode="Botrule Lrule Rrule"> Rash<sup>b</sup> </td> <td align="center" valign="middle" styleCode="Botrule Rrule">14 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">1.4 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">4.9 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content> </td> </tr> <tr> <td align="left" valign="middle" styleCode="Botrule Lrule Rrule"> Cough<sup>b</sup> </td> <td align="center" valign="middle" styleCode="Botrule Rrule">13 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">0 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">9 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Nervous System Disorders </content> </td> </tr> <tr> <td align="left" valign="middle" styleCode="Botrule Lrule Rrule"> Headache<sup>b</sup> </td> <td align="center" valign="middle" styleCode="Botrule Rrule">10 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">0.5 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">9 </td> <td align="center" valign="middle" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="5" align="left" valign="middle" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Investigations</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Weight decreased </td> <td align="center" valign="top" styleCode="Botrule Rrule">10 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">4.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.